Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

被引：0
|
作者：
Hassan Dorani
Kajs-Marie Schützer
Troy C. Sarich
Ulrika Wall
Ulrika Logren
Lis Ohlsson
Ulf G. Eriksson
机构：
[1] AstraZeneca Research and Development,Experimental Medicine
[2] AstraZeneca LP,undefined
[3] Johnson and Johnson Pharmaceutical Research and Development,undefined
来源：
European Journal of Clinical Pharmacology | 2007年 / 63卷
关键词：
Ximelagatran; Melagatran; Antibiotic interactions; Oral direct thrombin inhibitors; P-glycoprotein pump (p-GP);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 581
页数：10
相关论文
共 50 条
  • [31] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
    Michael Wolzt
    Maria Wollbratt
    Mia Svensson
    Karin Wåhlander
    Margaretha Grind
    Ulf G. Eriksson
    European Journal of Clinical Pharmacology, 2003, 59 : 537 - 543
  • [32] Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    Stangier, Joachim
    CLINICAL PHARMACOKINETICS, 2008, 47 (05) : 285 - 295
  • [33] Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
    Stangier, Joachim
    Clemens, Andreas
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 : 9S - 16S
  • [34] Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate
    Joachim Stangier
    Clinical Pharmacokinetics, 2008, 47 : 285 - 295
  • [35] The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Stangier, Joachim
    Rathgen, Karin
    Staehle, Hildegard
    Gansser, Dietmar
    Roth, Willy
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (03) : 292 - 303
  • [36] A comparison of the pharmacodynamics of heparin and argatroban (a direct thrombin inhibitor) in healthy volunteers.
    Hursting, MJ
    Joffrion, JL
    Brooks, RL
    Swan, SK
    BLOOD, 1996, 88 (10) : 657 - 657
  • [37] Comparison of the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in patients with nonvalvular atrial fibrillation and elderly healthy subjects.
    Eriksson, UG
    Wollbratt, M
    Wolzt, M
    Svensson, M
    Grind, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P95 - P95
  • [38] Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
    Huang, H. -L. A.
    Vaidyanathan, S.
    Yeh, C. -M.
    BiZot, M. -N.
    Dieterich, H. A.
    Dole, W. P.
    Howard, D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (09) : 2449 - 2456
  • [39] Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis
    Wåhlander, K
    Lapidus, L
    Olsson, CG
    Thuresson, A
    Eriksson, UG
    Larson, G
    Eriksson, H
    THROMBOSIS RESEARCH, 2002, 107 (3-4) : 93 - 99
  • [40] Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin
    Stangier, Joachim
    Staehle, Hildegard
    Rathgen, Karin
    Roth, Willy
    Reseski, Kathrin
    Koernicke, Thomas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (02): : 243 - 250
12345